HPV Screening with Self Collection Endorsed by Three Organizations

HPV screening with self collection endorsed by two organizations

Three organizations—the American Cancer Society (ACS), the American College of Obstetricians and Gynecologists (ACOG), and the Health Resources and Services Administration (HRSA), part of the Health and Human Services Department (HHS)—have each recently endorsed new guidelines for cervical cancer screening.

The three sets of guidelines agree on most issues, but there are a few differences.

Where the Guidelines on HPV Screening Agree

  • The HPV Primary Test is Preferred. All groups recommend that providers use an HPV primary test for patients of average risk between the ages of 30-65. This test looks for the types of HPV (human papillomavirus) that are known to cause about 70% of cervical cancers.
    • If the HPV primary test is not available, the groups recommend co-testing. Co-testing involves an HPV test done at the same time as a Pap test (also called cytology).
    • If this is not available, the groups all say that providers can use a Pap test alone.
  • Self-collection is acceptable. The FDA recently approved HPV tests that use self-collected samples. All three organizations say that these tests are an acceptable screening method. But  both ACS and ACOG continue to see provider-collected samples as the standard or preferred screening method.
    • The ACS recognizes that seeing a health care provider for testing can be difficult for some people or in some areas. In those cases, it says that self-collected HPV tests are an acceptable alternative.
    • ACOG says that self-collected samples are appropriate as long as there are systems in place for notification and follow up care.
    • HRSA does not make any distinctions between provider-collected or self-collected samples.
    • Both ACOG and ACS note that self-collection should only be done using tests and collection devices approved by the US Food and Drug Administration (FDA). Many of the tests sold online are not FDA approved for self-collection.
  • Follow up after normal results in three or five years. How often a person should get screened depends on which test(s) they were given and how the samples were collected.
    • People who get HPV primary testing or co-testing using a provider-collected sample and have normal results should be screened again in five years.
    • Both the ACS and ACOG say that people who collect their own samples for HPV testing and have normal results should be screened again in three years. This distinction is not included in the HRSA guidelines.
    • People who only get a Pap test and have normal results should be screened again in three years.
    • Anyone who has abnormal results will likely need to be screened more frequently.
  • Screening can end after age 65 if tests results were normal. All three organizations agree that most people who have an average risk level can stop screening after age 65.
    • The ACS and ACOG both specify that people should stop screening at 65 only if they’ve had a decade of normal results. This means that they had negative HPV tests at 60 and 65 or that they had three consecutive Pap tests that were negative, and the last one was at age 65.
    • HRSA guidelines also say screening can end at 65, but they are less specific about past results.

Where the Guidelines Differ

  • ACOG and HRSA suggest starting screening at 21. Both ACOG and HRSA recommend that people get Pap tests every three years between ages 21 and 29 and start HPV primary testing or co-testing at age 30.
  • ACS suggests starting screening at 25. The ACS recommends people start screening at age 25 and says that HPV primary testing is the preferred method for all age groups.

What this Means for Patients

For most patients, the screening test they get will depend on what their provider offers. Now that all three of these organizations have said they prefer HPV primary testing to co-testing, it is likely that more providers will offer that option.

HRSA’s guidelines also carry weight with insurance companies. Most private insurances companies are required to offer all recommended testing options as well as all follow-up testing without copays. (These recommendations affect insurance policies starting in 2027.)

HPV screening with self-collection will hopefully expand cervical cancer screening beyond gynecologists’ offices. Patients could be screened at a primary care provider’s office, an urgent care clinic, a mobile clinic, or even in some pharmacies. Or they could choose to collect their sample at home. This can help people who don’t have access to a gynecologist, or those who don’t feel comfortable with vaginal exams.

Of course, the most important thing is that everyone with a cervix get screened for cervical cancer regularly. Anyone who has questions about whether they need to be screened or which test is best, should talk to a health care provider.

More to HPV and Cervical Cancer Prevention

Hands holding a teal ribbon

How to Prevent HPV and Cervical Cancer

Though usually harmless, some types of HPV cause cervical lesions that, over a period of time, can develop into cancer if untreated.
An image of HPV

HPV-Related Cancer

According to the Centers for Disease Control and Prevention (CDC), about 36,500 HPV-associated cancers occur in the U.S each year.
HPV Awareness

Too Few People Understand the Link Between HPV and Cancer

A new study revealed a disturbing trend in health knowledge; fewer people seem to understand the connection between HPV and certain types of cancer including cervical, oral, anal, and penile cancers.
HPV vaccines

Is One Shot of the HPV Vaccine Enough? New Study Shows Promising Results

Is one shot enough? A recent study adds to evidence that one dose of the HPV vaccine might be enough to provide protection against cervical cancer.
Cervical Health Awareness Month

Celebrating Cervical Health Awareness Month in January

Cervical Health Awareness Month in January is a time to learn about cervical health and cancer prevention. The World Health Organization has a plan for the elimination of cervical cancer through vaccination and screening—we can get there!
HPV vaccination saves lives

Even More Evidence for the Value of Early HPV Vaccination

An exciting new study in Scotland found no cases of invasive cervical cancer in young women who had gotten the HPV vaccine by the time they were 14.
A uterus

New Option for Cervical Cancer Screening — Self Collected Samples

The FDA recently approved HPV testing using self-collected samples. Experts hope allowing people to collect their own samples will increase screening rates.
No speculum needed

What You Need to Know About the HPV Self-Collection Test

There’s a new way to screen for cervical cancer—no pelvic exam, stirrups, or speculum involved.
A doctor injects an HPV vaccine into an adolescent

The HPV Vaccine Prevents Cancer

In the U.S., HPV infections are estimated to cause about 37,300 cases of cancer. The HPV vaccine can prevent over 90% of these cancers from ever developing.
Cervical pre-cancer

New Study Shows a Dramatic Drop in Cervical Pre-Cancers

A study has found a dramatic drop in the rates of cervical pre-cancers in young adult women—evidence that the HPV vaccine is working.